Current Edition

Pharmapack 2018: PCI to Showcase Serialization Expertise and EU Commitment from Continued Service Investments and Site Expansions

International pharmaceutical outsourcing services provider PCI Pharma Services (PCI) will be at Pharmapack 2018(February 7-8, Paris expo Porte de Versailles, stand J24, hall 7.1). Specialists from PCI will showcase their significant Serialization expertise and EU presence at the event, highlighting the organization’s ongoing program of investment and expansion to triple its market-leading Serialization capacity in Europe, alongside North America.

PCI has serializing commercial drug product for more than six years, significantly expanding global capacity well in advance of meeting the implementation deadlines for the European Falsified Medicines Directive (EU FMD). Building on the organization’s existing Serialization experience, the program has entailed a series of technological and facility developments at its sites in Europe and North America to benefit its global supply network.

Visitors at Pharmapack 2018 have the chance to find out more about PCI’s Serialization specialism and how its enhanced capabilities can support their own preparations to comply with the new regulations.

Gareth Lewis, Commercial and Supply Chain Director at PCI Pharma Services, said: “Pharmapack is a great opportunity for us to share our increasing Serialization expertise and meet visitors who are keen to understand more about how our experience can help them in this important area. We will be at our stand ready to answer any questions, update people on the latest developments and support attendees with their packaging needs and Serialization challenges.”

As well as Serialization, PCI has been actively investing in its core business and key site expansion in Cold Chain infrastructure and capacity.  PCI has expanded its EU footprint with its most recent acquisition in Ireland, and site expansions at its Tredegar and Bridgend facilities in the UK, helping provide a supply solution to support pharmaceutical and biotech companies looking to address potential concerns regarding Brexit uncertainty.